Amgen's net margin has remained consistently in the 20-30% range over the past 12 quarters, demonstrating its ability to translate robust revenue into substantial bottom-line profits. Over the same period, the company has generated between $6.1 billion and $8.1 billion in free cash flow per quarter, providing ample financial flexibility. Amgen's balance sheet is also in excellent shape, with $16.8 billion in cash and $40.9 billion in total assets as of the most recent quarter. This combination of consistent profitability, strong cash flow, and a healthy balance sheet should allow Amgen to weather near-term market volatility and economic uncertainty. Given these favorable fundamentals, I believe Amgen's shares are an attractive investment option for long-term investors seeking stability in the current environment. In Q4 2025, Alibaba reported revenue of $144.5 billion , up 32% year-over-year, indicating its ability to capture consumer demand despite a slowing economy. However, the company's net margin declined to 13.1%, down from 19.1% a year earlier, as it faced rising costs and competitive pressures. This margin compression contributed to Alibaba's net income growth slowing to 32%, compared to 57% in the prior year quarter. These trends suggest Alibaba may need to focus more on profitability in the near term rather than pure top-line growth. While Alibaba remains a dominant player in the Chinese e-commerce market, the current data points to a more neutral outlook in the short run as the company navigates a challenging retail environment.

Research these companies